“Never has the threat of antimicrobial resistance been more immediate and the need for solutions more urgent.” (Dr. Tedros Adhanom Ghebreyesus, Director-General of WHO, 2020)

Learn more

“If we don’t act now, our medicine cabinet will be empty and we won’t have the antibiotics we need to save lives.” (Tom Frieden MD, former Director of the Centres for Disease Control and Prevention (CDC))

Learn more

SuperTrans Medical - Eradicating resistant bacteria with Superdrugs

Learn more

About SuperTrans Medical

Antimicrobial resistance (AMR) is a growing health emergency, with the World Health Organisation (WHO) describing it as one of the biggest threats to global health. In direct response to this unmet medical need, SuperTrans Medical is developing novel antibiotics through the revitalisation of existing FDA-approved drug molecules, resulting in superior properties.
Company Overview

SuperTrans Medical Limited (STM) is a biopharmaceutical company developing novel antibiotics that target difficult-to-treat, multi-drug resistant (MDR) bacteria, also known as superbugs. This global health threat is directly addressed by STM through our unique core competency to revitalise and broaden the spectrum of existing FDA-approved drugs, thereby enabling the targeting of urgent threat pathogens. STM is committed to an expedited development program and a likely shorter path to the clinic.

Our Team

Our dedicated and passionate leadership and R&D teams have more than 200 years of accumulated experience in drug development and the pharmaceutical industry. Specifically, STM's scientists have an outstanding track record of discovery and development of novel anti-infectives (including marketed drugs) from previous involvement in biotech, academia and big pharma.

Our Technology

We are developing novel antibiotics through the intelligent repurposing of existing medicines by using our unique permeator technology. Chemical attachment of the permeator unit to FDA-approved antibiotics, results in a broader spectrum of activity which enables the efficient targeting of superbugs. These features are evidenced by significantly improved capabilities in eradicating biofilms and multi-drug resistant pathogens, including difficult-to-treat carbapenem-resistant Enterobacteriacae and Acinetobacter baumannii, categorised as urgent threat pathogens by the Centers for Disease Control and Prevention (CDC).

Latest News & Articles
About Antibiotic Resistance

Around 700,000 people around the world die annually due to drug-resistant infections. If no action is taken, it has been estimated that drug-resistant infections will kill 10 million people a year by 2050.